Temporal trends in treatment and outcomes for advanced heart failure with reduced ejection fraction from 1993–2010: findings from a university referral center
10.1161/circheartfailure.112.000178 · 2013
Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras
10.1161/circheartfailure.110.959882 · 2011
10.1093/eurjhf/hfs033
10.1093/eurjhf/hfs033 · 2012
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
10.1016/j.jacc.2013.05.019 · 2013
Multiple essential functions of neuregulin in development
10.1038/378386a0 · 1995
Cardiac dysfunction in the trastuzumab clinical trials experience
10.1200/jco.2002.20.5.1215 · 2002
Adjuvant trastuzumab in HER2-positive breast cancer
10.1056/nejmoa0910383 · 2011
Neuregulin-1β for the treatment of systolic heart failure
10.1016/j.yjmcc.2011.06.016 · 2011
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy
10.1016/j.jacc.2006.05.057 · 2006
Anti-remodeling and anti-fibrotic effects of the neuregulin-1 beta glial growth factor 2 in a large animal model of heart failure
10.1161/jaha.113.000773 · 2014
Neuregulin in cardiovascular development and disease
10.1161/circresaha.112.267286 · 2012
Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction
10.1371/journal.pone.0055741 · 2013
Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses
10.1093/eurjhf/hfq152 · 2011
A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure
10.1016/j.jacc.2009.12.044 · 2010
ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family
10.1016/0092-8674(93)90407-h · 1993
Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system
10.1038/362312a0 · 1993
The immunoglobulin-like domain is involved in interaction of Neuregulin1 with ErbB
10.1016/j.bbrc.2006.09.028 · 2006
Neuregulin-heparan-sulfate proteoglycan interactions produce sustained erbB receptor activation required for the induction of acetylcholine receptors in muscle
10.1074/jbc.m104485200 · 2001
Neuregulins: versatile growth and differentiation factors in nervous system development and human disease
10.1016/j.brainresrev.2005.11.006 · 2006
Targeting human epidermal growth factor receptor signaling with the neuregulin’s heparin-binding domain
10.1074/jbc.m109.032714 · 2009
The N-terminal domains of neuregulin 1 confer signal attenuation
10.1074/jbc.m512887200 · 2006
Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt
10.1016/j.yjmcc.2003.09.012 · 2003
Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity
10.1161/01.cir.0000013839.41224.1c · 2002
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins
10.1152/ajpheart.01010.2008 · 2009
The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting
10.1016/j.hfc.2011.03.008 · 2011
Unresolved referenced work
Kept as external metadata until matched
10.1016/j.echo.2005.10.005
10.1016/j.echo.2005.10.005 · 2005
American Society of Echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography
10.1016/j.echo.2008.09.009 · 2008
Unresolved referenced work
Kept as external metadata until matched
ERBB2 inhibition and heart failure
10.1056/nejmcibr1203156 · 2012
Neuregulin as a heart failure therapy and mediator of reverse remodeling
10.1007/s11897-013-0176-2 · 2014
